GB
Genicity develops an allogeneic T-cell therapy platform combining bispecific antibodies with engineered T-cells for cancer treatment. Their ENABLR technology modifies donor T-cells to recognize and eliminate cancer cells when paired with specific bispecific antibodies. This approach aims to provide an off-the-shelf immunotherapy solution for patients with high unmet medical needs.
Updated 4 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Genicity develops an allogeneic T-cell therapy platform combining bispecific antibodies with engineered T-cells for cancer treatment. Their ENABLR technology modifies donor T-cells to recognize and eliminate cancer cells when paired with specific bispecific antibodies. This approach aims to provide an off-the-shelf immunotherapy solution for patients with high unmet medical needs.